Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial.

D. D. Rhoads, R. D. Wolcott, M. A. Kuskowski, B. M. Wolcott, L. S. Ward, A. Sulakvelidze

Research output: Contribution to journalArticlepeer-review

231 Scopus citations

Abstract

OBJECTIVE: This phase 1 trial set out to examine the safety of a bacteriophage-based preparation for difficult-to-treat wounds. METHOD: The intention-to-treat sample comprised 42 patients with chronic venous leg ulcers (VLUs); 39 patients completed the trial. The ulcers were treated for 12 weeks with either a saline control or bacteriophages targeted against Pseudomonas aeruginosa, Staphylococcus aureus and Escherichia coli. Follow-up continued until week 24. RESULTS: No adverse events were attributed to the study product. No significant difference (p>0.05) was determined between the test and control groups for frequency of adverse events, rate of healing, or frequency of healing. CONCLUSION: This study found no safety concerns with the bacteriophage treatment. Efficacy of the preparation will need to be evaluated in a phase II efficacy study. DECLARATION OF INTEREST: One of the authors (AS) holds an equity interest in Intralytix. The other authors do not have any interest in commercial activities.

Original languageEnglish (US)
Pages (from-to)237-238, 240-243
JournalJournal of wound care
Volume18
Issue number6
DOIs
StatePublished - Jun 2009

Fingerprint Dive into the research topics of 'Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial.'. Together they form a unique fingerprint.

Cite this